Eli Lilly and Co
1LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
stocks
How to focus on the right things this reporting season
For individual investors, it is important to frame earnings season revelations in a long-term way.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.30 | 32.70 | 0.36% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,449.93 | 474.84 | 1.08% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 24,969.68 | 62.87 | 0.25% |
| NASDAQ | 21,643.13 | 257.72 | 1.21% |
| Nikkei 225 | 42,718.17 | 897.69 | 2.15% |
| NZX 50 Index | 12,759.68 | 152.18 | -1.18% |
| S&P 500 | 6,436.48 | 63.03 | 0.99% |
| S&P/ASX 200 | 8,880.80 | 36.00 | 0.41% |
| SSE Composite Index | 3,665.92 | 18.37 | 0.50% |